'Decoy' and 'non-decoy' functions of DcR3 promote malignant potential in human malignant fibrous histiocytoma cells

International Journal of Oncology

Volumn 43, Issue 3, 2013, Pages 703-712

  Toda, Mitsunori ^a   Kawamoto, Teruya ^a   Ueha, Takeshi ^b   Kishimoto, Kenta ^a   Hara, Hitomi ^a   Fukase, Naomasa ^a   Onishi, Yasuo ^a   Harada, Risa ^a   Minoda, Masaya ^a   Kurosaka, Masahiro ^a   Akisue, Toshihiro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NeoChemir Inc   (Japan)

Author keywords

Apoptosis; DcR3; Invasion; Matrix metalloproteinase; Migration

Indexed keywords

DECOY RECEPTOR 3; FAS LIGAND; GELATINASE A; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT FIBROUS HISTIOCYTOMA; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH;

APOPTOSIS; CARCINOGENESIS; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; MATRIX METALLOPROTEINASE 2; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84880588200     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1999     Document Type: Article

References (46)

1. Spira AI and Ettinger DS: The use of chemotherapy in soft-tissue sarcomas. Oncologist 7: 348-359, 2002.
2. Matushansky I, Charytonowicz E, Mills J, Siddiqi S, Hricik T and Cordon-Cardo C: MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century. Expert Rev Anticancer Ther 9: 1135-1144, 2009.
3. Papai Z, Bodoky G, Szanto J, et al: The efficacy of a combination of etoposide, ifosfamide and cisplatin in the treatment of patients with soft tissue sarcoma. Cancer 89: 177-180, 2000.
4. Jain A, Sajeevan K, Babu K and Lakshmaiah K: Chemotherapy in adult soft tissue sarcoma. Indian J Cancer 46: 274-287, 2009.
5. Pitti RM, Marsters SA, Lawrence DA, et al: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396: 699-703, 1998.
6. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R and Kwon BS: A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 274: 13733-13736, 1999.
7. Migone TS, Zhang J, Luo X, et al: TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16: 479-492, 2002.
8. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
9. Strasser A, Jost PJ and Nagata S: The many roles of FAS receptor signaling in the immune system. Immunity 30: 180-192, 2009.
10. Ho CH, Chen CL, Li WY and Chen CJ: Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion. Carcinogenesis 30: 1443-1451, 2009.
11. Ge Z, Sanders AJ, Ye L, Wang Y and Jiang WG: Expression of death decoy receptor-3 (DcR3) in human breast cancer and its functional effects on breast cancer cells in vitro. J Exp Ther Oncol 9: 109-118, 2011.
12. Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL and Lin WW: Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res 64: 1122-1129, 2004.
13. Yang CR, Wang JH, Hsieh SL, Wang SM, Hsu TL and Lin WW: Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. Cell Death Differ 11 (Suppl 1): S97-S107, 2004.
14. Wu SF, Liu TM, Lin YC, et al: Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication. J Leukoc Biol 75: 293-306, 2004.
15. Hayashi S, Nishiyama T, Miura Y, et al: DcR3 induces cell proliferation through MAPK signaling in chondrocytes of osteoarthritis. Osteoarthritis Cartilage 19: 903-910, 2011.
16. You RI, Chang YC, Chen PM, et al: Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3). Blood 111: 1480-1488, 2008.
17. Hsu MJ, Lin WW, Tsao WC, et al: Enhanced adhesion of monocytes via reverse signaling triggered by decoy receptor 3. Exp Cell Res 292: 241-251, 2004.
18. Ohshima K, Haraoka S, Sugihara M, et al: Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer Lett 160: 89-97, 2000.
19. Roth W, Isenmann S, Nakamura M, et al: Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 61: 2759-2765, 2001.
20. Tsuji S, Hosotani R, Yonehara S, et al: Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Int J Cancer 106: 17-25, 2003.
21. Imabori M, Akisue T, Kishimoto K, et al: Expression of DcR3 in bone and soft tissue tumors. Cancer Ther 7: 43-48, 2009.
22. Macher-Goeppinger S, Aulmann S, Wagener N, et al: Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 10: 1049-1056, 2008.
23. Chen G and Luo D: Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma. Ups J Med Sci 113: 297-304, 2008.
24. Chen G and Luo D: Expression of decoy receptor 3 in liver tissue microarrays. Natl Med J India 21: 275-278, 2008.
25. Chang PM, Chen PM, Hsieh SL, et al: Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome. Int J Oncol 33: 549-554, 2008.
26. Fujita Y, Sakakura C, Shimomura K, et al: Chromosome arm 20q gains and other genomic alterations in esophageal squamous cell carcinoma, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Hepatogastroenterology 50: 1857-1863, 2003.
27. Takahama Y, Yamada Y, Emoto K, et al: The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 5: 61-68, 2002.
28. Choong PFM: The molecular basis of skeletal metastases. Clin Orthop Relat Res 415: S19, 2003.
29. Hidalgo M and Eckhardt SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93: 178-193, 2001.
30. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 163-176, 2002.
31. Ohnishi Y, Ito Y, Tajima S, Ishibashi A and Arai K: Immunohistochemical study of membrane type-matrix metalloproteinases (MT-MMPs) and matrix metalloproteinase-2 (MMP-2) in dermatofibroma and malignant fibrous histiocytoma. J Dermatol Sci 28: 119-125, 2002.
32. Ahlen J, Enberg U, Larsson C, et al: Malignant fibrous histiocytoma, aggressive fibromatosis and benign fibrous tumors express mRNA for the metalloproteinase inducer EMMPRIN and the metalloproteinases MMP-2 and MT1-MMP. Sarcoma 5: 143-149, 2001.
33. Nakatani T, Marui T, Yamamoto T, Kurosaka M, Akisue T and Matsumoto K: Establishment and characterization of cell line TNMY1 derived from human malignant fibrous histiocytoma. Pathol Int 51: 595-602, 2001.
34. Kiyozuka Y, Nakagawa H, Uemura Y, et al: Novel cell lines established from a human myxoid malignant fibrous histiocytoma arising in the uterus. Cancer Genet Cytogenet 127: 7-15, 2001.
35. Liang CC, Park AY and Guan JL: In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329-333, 2007.
36. Albini A: Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res 4: 230-241, 1998.
37. Troeberg L and Nagase H: Zymography of metalloproteinases. Curr Protoc Protein Sci Chapter 21: Unit 21, 15, 2004.
38. Yang CR, Guh JH, Teng CM, Chen CC and Chen PH: Combined treatment with denbinobin and Fas ligand has a synergistic cytotoxic effect in human pancreatic adenocarcinoma BxPC-3 cells. Br J Pharmacol 157: 1175-1185, 2009.
39. Reuben PM and Cheung HS: Regulation of matrix metalloproteinase (MMP) gene expression by protein kinases. Front Biosci 11: 1199-1215, 2006.
40. Kim R, Emi M and Tanabe K: Cancer immunoediting from immune surveillance to immune escape. Immunology 121: 1-14, 2007.
41. Yang D, Fan X, Yin P, et al: Significance of decoy receptor 3 (Dcr3) and external-signal regulated kinase 1/2 (Erk1/2) in gastric cancer. BMC Immunol 13: 28, 2012.
42. Chin YR and Toker A: Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal 21: 470-476, 2009.
43. Sun M, Wang G, Paciga JE, et al: AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159: 431-437, 2001.
44. Staal SP: Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 84: 5034-5037, 1987.
45. Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67, 2010.
46. Morrison CJ, Butler GS, Bigg HF, Roberts CR, Soloway PD and Overall CM: Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway. J Biol Chem 276: 47402-47410, 2001.